Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.
Investor Relations
February 22, 2024 8:30 AM EST
Kymera Therapeutics Fourth Quarter and Full Year 2023 Results Call
View All Events
Investor Toolkit
Latest Press Releases
View our most latest Press Releases.
Latest Quarterly Results
View our most recent Quarterly Earnings.
View Our Filings
Our most up-to-date summary of our financial performance.
Kymera Cares
Our team’s shared commitment to improving people’s lives extends beyond our work to develop groundbreaking new medicines.
Stay Connected
Investor & Media Contact
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com